ABT Trading Analysis - 10/22/2026 10:21 AM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below:

• Abbott Laboratories (ABT) recently reported quarterly results showing steady medical device and diagnostics growth, with continued momentum in glucose monitoring (FreeStyle Libre).
• ABT went ex-dividend on 2026-10-15 with a dividend rate of $2.52 annually (yield ~2.46%), a routine catalyst that can cause minor price softness post-date.
• FDA clearance for a new cardiovascular device was announced in prior weeks, a potential medium-term tailwind for the structural heart segment.
• Broad healthcare sector has lagged the market amid rate-cut uncertainty, though ABT's low beta (0.34) limits systemic sensitivity.
• No major earnings catalyst before the next major option expiration (2026-11-20) per general calendar knowledge; news context suggests fundamental stability but not explosive growth.

Context: News reflects a stable large-cap healthcare name with modest catalysts. This contrasts with the embedded data showing bearish technicals but bullish options sentiment.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data:

• Trailing P/E: 32.70; Trailing EPS: $3.14. No forward P/E, PEG, or price/book provided (null).
• Market Cap: $173,903,491,500; Shares Out: 1,730,383,000; Institutional Ownership: 59.41%.
• Dividend Yield: 2.46%; Rate: $2.52; Ex-Dividend: 2026-10-15. Fiscal Year End: 2025-12-01.
• Beta: 0.34 (low market sensitivity). 52W High: $132.03; 52W Low: $81.97.
• Historical Volatility: 21.01%; Average Volume: 9,846,000.
• Revenue growth, margins, ROE, Debt/Equity, FCF: null in data. Cannot assess directly.
• Analyst consensus / target mean price: null. No street alignment available.

Fundamentals show a fairly valued (P/E 32.70) defensive name with low beta and solid dividend. This stability diverges from the embedded bearish technical posture (price below SMA50) but aligns with bullish options conviction.

Current Market Position

Current price per indicators: $99.85 (as of 2026-10-21 close). Minute bars show 2026-10-22 09:50 last close $100.55, with open $101.50 and low $100.36 intraday.

Recent daily action: 2026-10-21 traded range $97.67–$106.35, closed $99.85 on volume 18,059,209 (vs 20d avg 5,950,256) — high volatility day. 2026-10-22 early bars show compression: 09:30 $101.50 → 09:50 $100.55, lower high sequence.

Intraday momentum:中性 to soft; early 2026-10-22 bars drift below prior close with thinning volume (last bar 82,882 vs first 406,566).

Technical Analysis

• SMA alignment: Price $99.85 < SMA20 $100.80 < SMA5 $103.22 < SMA50 $105.49 → bearish stack, no golden cross.
• RSI 58.50: mid-range, slight upside bias but not overbought.
• MACD: -0.32, signal -0.25, hist -0.06 → bearish momentum, weak negative divergence.
• Bollinger: mid $100.80, price inside lower half, no squeeze (band width $9.29).
• 30d range: high $106.35, low $95.06; price at 42.1% of range ($99.85).

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-22 10:21) methodology: Delta 40-60 only.

Call Volume: $30,780 (73.7%) Put Volume: $10,970 (26.3%) Total: $41,750

• Sentiment: Bullish (call contracts 61 vs put 40; trades 15 vs 6).
• Pure directional conviction: call dollar vol 2.8x puts, strong bullish tilt from informed flow.
• Divergence: technicals bearish (price below SMA50, MACD neg) but sentiment bullish → spread reco says "Wait for alignment".

Key Price Levels (Observational Only)